Table 1.

Patient demographics and response. CR, complete response; PR, partial response; N/A, not available.

Subject UPN	Age/sex karyotype	Previous therapies	CLL tumor burden at baseline			Total dose of CART19 (cells/kg)	Response day +30 (duration)
			BM (study day)‡	Blood (study day)‡	Nodes/spleen (study day)‡
01	65/M normal	Fludarabine × four cycles (2002)	Hypercellular 70% CLL	N/A	6.2 × 1011 to 1.0 × 1012 CLL cells (day −37)	1.1 × 109 (1.6 × 107/kg)	CR (11+ months)
		Rituximab/fludarabine × four cycles (2005)	2.4 × 1012 CLL cells (day −14)
		Alemtuzumab × 12 weeks (2006)	1.7 × 1012 CLL cells (day −1)
		Rituximab (two courses, 2008 to 2009)
		R-CVP × two cycles (2009)
		Lenalidomide (2009)
		PCR × two cycles (5/18/2010 to 6/18/2010)
		Bendamustine × one cycle (7/31/10 to 8/1/10) pre-CART19
02	77/M del (17)(p13)*	Alemtuzumab × 16 weeks (6/2007)	Hypercellular >95% CLL	2.75 × 1011 CLL cells (day −1)	1.2 × 1012 to 2.0 × 1012 CLL cells (day −24)	5.8 × 108 (1.0 × 107/kg)	PR (7 months)
		Alemtuzumab × 18 weeks (3/2009)	3.2 × 1012 CLL cells (day −47)
		Bendamustine/rituximab:
		7/1/2010 (cycle 1)
		7/28/2010 (cycle 2)
		8/26/2010 (cycle 3) pre-CART19
03	64/M del (17)(p13)†	R-Fludarabine × two cycles (2002)	Hypercellular 40% CLL	N/A	3.3 × 1011 to 5.5 × 1011 CLL cells (day −10)	1.4 × 107 (1.46 × 105/kg)	CR (10+ months)
		R-Fludarabine × four cycles (10/06 to 1/07)	8.8 × 1011 CLL cells (day −1)
		R-Bendamustine × one cycle (2/09)
		Bendamustine × three cycles (3/09 to 5/09)
		Alemtuzumab × 11 weeks (12/09 to 3/10)
		Pentostatin/cyclophosphamide (9/10/10) pre-CART19

^*UPN 02 karyotype [International System for Human Cytogenetic Nomenclature (ISCN)]: 45,XY,del(1)(q25),+del(1)(p13),t(2;20)(p13;q11.2),t(3;5)(p13;q35),add(9)(p22),?del(13)(q14q34), −14,del(17) (p13)[cp24].

^†UPN 03 karyotype (ISCN): 46,XY,del(17)(p12)[18]/44~46,idem,der(17)t(17;21)(p11.2;q11.2)[cp4]/40~45,XY, −17[cp3].

^‡See the Supplementary Material for methods of tumor burden determination.